Loading...
XASX
SNT
Market cap9mUSD
Jan 02, Last price  
0.02AUD
Name

Pharmaxis Ltd

Chart & Performance

D1W1MN
P/E
—
P/S
2.38
EPS
—
Div Yield, %
—
Shrs. gr., 5y
11.98%
Rev. gr., 5y
-4.56%
Revenues
6m
-22.37%
05008,0002,357,000527,0001,025,0001,170,0001,202,0001,466,0003,237,0005,036,00057,741,00014,335,00013,286,0007,282,0005,676,0007,027,0006,680,0007,426,0005,765,000
Net income
-11m
L+486.78%
-6,000,669-10,232,357-17,733,000-24,179,000-20,440,000-35,171,000-46,345,000-45,758,000-38,644,000-43,537,000-51,818,00018,466,000-16,463,000-18,346,0006,428,000-20,058,000-13,943,000-2,970,000-1,936,000-11,360,000
CFO
-7m
L-55.36%
-4,652,150-9,274,214-13,775,000-20,697,000-18,850,000-26,469,000-39,683,000-37,366,000-38,142,000-35,383,000-28,132,00021,780,000-11,989,000-15,262,0000-19,798,000-13,284,0003,072,000-16,303,000-7,277,000

Profile

Pharmaxis Ltd engages in the research, development, and commercialization of healthcare products for the treatment of fibrotic and inflammatory diseases worldwide. The company operates through two segments, Mannitol Respiratory Business and New Drug Development. It offers Bronchitol, an inhaled dry powder for the treatment of cystic fibrosis; and Aridol, an airways inflammation test that is used to identify twitchy or hyper-responsive airways, as well as to assist in diagnosing and managing asthma. The company's product pipeline consists of oral pan-lysyl oxidase inhibitors (LOX) targeting myelofibrosis and other cancers; topical pan-LOX inhibitors targeting skin scarring after events, such as accidents, surgery,and burns; selective Lysyl Oxidase Like Inhibitors (LOXL2) targeting chronic fibrotic diseases, including kidney fibrosis, pulmonary fibrosis, liver fibrosis, and cardiac fibrosis; and semicarbazide-sensitive amine oxidase for neuro inflammatory diseases. It is also developing Orbital, a dry powder inhaler to deliver high drug doses to lungs. Pharmaxis Ltd was incorporated in 1998 and is headquartered in Frenchs Forest, Australia.
URL
https://www.pharmaxis.com.au/
IPO date
Nov 10, 2003
Employees
69
Domiciled in
AU
Incorporated in
AU

Valuation

Title
AUD in thousands, except ratios and share amounts
FYFYFYFYFYFYFYFY
2023‑062022‑062021‑062020‑062019‑062018‑062017‑062016‑06
Income
Revenues
5,765
-22.37%
Cost of revenue
27,247
Unusual Expense (Income)
NOPBT
(21,482)
NOPBT Margin
Operating Taxes
14,257
Tax Rate
NOPAT
(35,739)
Net income
(11,360)
486.78%
Dividends
(2,247)
Dividend yield
6.99%
Proceeds from repurchase of equity
9,259
BB yield
-28.82%
Debt
Debt current
2,043
Long-term debt
2,043
Deferred revenue
Other long-term liabilities
6,434
Net debt
(5,144)
Cash flow
Cash from operating activities
(7,277)
CAPEX
(138)
Cash from investing activities
(131)
Cash from financing activities
6,979
FCF
(31,601)
Balance
Cash
9,230
Long term investments
Excess cash
8,942
Stockholders' equity
9,559
Invested Capital
9,094
ROIC
ROCE
EV
Common stock shares outstanding
655,624
Price
0.05
-24.62%
Market cap
32,126
-12.20%
EV
26,982
EBITDA
(19,672)
EV/EBITDA
Interest
223
Interest/NOPBT